PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Saxenda, like Ozempic and Wegovy ... Weight loss injections and fat burning pills are vastly different. Fat burning pills and other “quick-fix” weight loss supplements are typically sold ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Also Read: Novo Nordisk’s Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows Novo Nordisk asserts that compounded liraglutide products have a ...

Novo Nordisk (NVO) markets liraglutide under the brand names Victoza, Saxenda and Xultophy. The drug is currently on the FDA's drug shortage list. Compounding pharmacies are allowed to make ...

Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to ...